NL-OMON25781CompletedNot Applicable
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumor uptake of 89Zr-labeled cetuximab assessed by PET.
VU Univeristy Medical Center0 sites25 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •1. Advanced colorectal adenocarcinoma;
- •2. Subjects must have been treated according to standard care with a fluoropyrimidine (e.g. fluorouracil or capecitabine), irinotecan, and oxaliplatin or had contra-indications to treatment with these drugs;
Exclusion Criteria
- •1. Previous exposure to an anti-EGFR therapy;
- •2. Significant skin condition interfering with treatment;
Investigators
Similar Trials
Completed
Not Applicable
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PETmetastazised colorectal canceradvanced intestinal cancer10017991NL-OMON36409Vrije Universiteit Medisch Centrum38
Active, not recruiting
Phase 1
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET - COLO CETUXadvanced colorectal cancerMedDRA version: 12.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2010-021943-41-NLVU Medical Center38
Recruiting
Not Applicable
Optimalisatie van de behandeling met cetuximab voor patienten met uitgezaaide dikkedarm kanker door de opname van 89-zirconium gelabeld cetuximab te beoordelen middels PET-scaMetastatic colorecal adenocarcinoma, K-RAS and N-RAS wild type.NL-OMON26385VU University Medical Center (central site)UMC GroningenRadboud UMC85
Terminated
Phase 1
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT02117466Amsterdam UMC, location VUmc85
Terminated
Phase 2
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without BevacizumabColorectal NeoplasmsNCT00321100Fox Chase Cancer Center23